Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells

187Citations
Citations of this article
105Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Extracorporeal photopheresis (ECP), a technique that exposes isolated white blood cells to photoactivatable 8-methoxypsoralen and ultraviolet A radiation, is used clinically to treat cutaneous T-cell lymphoma and immune-mediated diseases such as graft-versus-host disease (GVHD). ECP is thought to control these diseases in part through direct induction of lymphocyte apoptosis, but its effects on the immune system beyond apoptosis remain poorly characterized. We have developed a novel method for incorporating ECP treatment into well-established and clinically relevant murine models of GVHD to examine its effects during an ongoing immune response. We demonstrate that the transfer of cells treated with ECP reverses established GVHD by increasing donor regulatory T cells and indirectly reducing the number of donor effector lymphocytes that themselves had never been exposed to psoralen and ultraviolet A radiation. © 2008 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Gatza, E., Rogers, C. E., Clouthier, S. G., Lowler, K. P., Tawara, I., Liu, C., … Ferrara, J. L. M. (2008). Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood, 112(4), 1515–1521. https://doi.org/10.1182/blood-2007-11-125542

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free